Research
Hormonal
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RA) reduced the risk of any cardiovascular event in overweight or obese adults without diabetes.
GLP-1 RA can be considered for reducing cardiovascular risk in overweight or obese patients without diabetes.
StrongSupportsmedium confidence
In overweight or obese adults without diabetes, treatment with GLP-1 RA reduced the risk of cardiovascular events.
Why this rating
Based on a meta-analysis of placebo-controlled randomized controlled trials.
Source
Effect of glucagon‐like peptide‐1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta‐analysis of placebo‐controlled randomized trials
Ana Rita Leite et al. · Diabetes Obesity and Metabolism · 2022
Meta-analysisCited 34×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →